Literature DB >> 7861704

Mechanisms of polymorphonuclear leukocyte mediated peritoneal mesothelial cell injury.

S P Andreoli1, C Mallett, K Williams, J A McAteer, R Rothlein, C M Doerschuk.   

Abstract

To determine the susceptibility of human peritoneal mesothelial cells to injury mediated by activated polymorphonuclear leukocytes (PMNs), we exposed cultured human peritoneal mesothelial cells to 1250, 2500, 3750, and 5000 PMNs/mm3 activated with 50 ng/ml phorbol myristate acetate (PMA) or with 10(-7) FMLP/cytochalasin B for one to five hours. PMN adhesion to mesothelial cells was determined with radiolabeled PMNs. Mesothelial cell injury was determined in five different cell lines by measuring ATP depletion and 51chromium release. In each mesothelial cell line, PMN adhesion was significantly (P < 0.001) increased when PMNs were activated; 64 +/- 1.0 to 92.5 +/- 7.0% of the activated PMNs were adherent to mesothelial cells compared to 6 +/- 1.8 to 27 +/- 2.4% of resting PMNs. Mesothelial cells responded to PMN mediated injury with a fall in ATP levels and 51chromium release that was significant (P < 0.05) by three to four hours. At five hours, ATP levels were markedly depressed to 5 to 41% of control values. Increasing concentrations of activated PMNs caused significantly (P < 0.05) greater mesothelial cell injury as determined by ATP depletion and 51chromium release. PMN adhesion, ATP depletion and 51chromium release were significantly (P < 0.01) prevented by an anti-CD18 monoclonal antibody that inhibits the CD11/CD18 adhesion molecule complex on PMNs. Similar injury and protection from injury was demonstrated when mesothelial cells were exposed to PMNs activated with FMLP/cytochalasin B.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7861704     DOI: 10.1038/ki.1994.372

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

1.  A three-dimensional in-vitro model for the study of peritoneal tumour metastasis.

Authors:  D G Jayne; R O'Leary; A Gill; A Hick; P J Guillou
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

Review 2.  Epidemiology and pathophysiology of intraabdominal infections (IAI).

Authors:  E H Farthmann; U Schöffel
Journal:  Infection       Date:  1998 Sep-Oct       Impact factor: 3.553

3.  Disruption of the integrity of human peritoneal mesothelium by interleukin-1beta and tumor necrosis factor-alpha.

Authors:  Sylvia Stadlmann; Ruth Raffeiner; Albert Amberger; Raimund Margreiter; Alain Gustave Zeimet; Burkhardt Abendstein; Patrizia Lucia Moser; Gregor Mikuz; Bernd Klosterhalfen; Felix Albert Offner
Journal:  Virchows Arch       Date:  2003-07-26       Impact factor: 4.064

Review 4.  Host defences in continuous ambulatory peritoneal dialysis and the genesis of peritonitis.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1995-10       Impact factor: 3.714

5.  Neutrophil emigration in the skin, lungs, and peritoneum: different requirements for CD11/CD18 revealed by CD18-deficient mice.

Authors:  J P Mizgerd; H Kubo; G J Kutkoski; S D Bhagwan; K Scharffetter-Kochanek; A L Beaudet; C M Doerschuk
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

6.  An injured tissue affects the opposite intact peritoneum during postoperative adhesion formation.

Authors:  Tatsuya Suzuki; Toru Kono; Hiroki Bochimoto; Yoshiki Hira; Tsuyoshi Watanabe; Hiroyuki Furukawa
Journal:  Sci Rep       Date:  2015-01-08       Impact factor: 4.379

7.  Neutrophil extracellular traps promote peritoneal metastasis of colon cancer cells.

Authors:  Amr A Al-Haidari; Nader Algethami; Mattias Lepsenyi; Milladur Rahman; Ingvar Syk; Henrik Thorlacius
Journal:  Oncotarget       Date:  2019-02-08

8.  Elastase, α1-proteinase inhibitor, and interleukin-8 in children and young adults with end-stage kidney disease undergoing continuous ambulatory peritoneal dialysis.

Authors:  Bożena Polańska; Daria Augustyniak; Irena Makulska; Maria Niemczuk; Adam Jankowski; Danuta Zwolińska
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2013-11-29       Impact factor: 4.291

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.